Clinical trials: Cancer Neck
Cervical Cancer Screening
Improving Cervical Cancer Screening in Women Living With HIV Attending Chronic Disease Clinics in Semi-rural Tanzania
This study is to analyse the effect of a bundle of measures on the proportion of females being screened for cervical cancer in the Kilombero and Ulanga Antiretroviral Cohort (KIULARCO), comparing the time period before…
- Trial name
- NCT05256862
- Testing
- Data collection
- Where
- Tanzania
- Volunteers
- 2,974 people
- Sponsor
- University Hospital, Basel, Switzerland
Cervical Cancer
Biomarker Evaluation in Advanced Stage Cervical Cancer by an International Working Group. Tumor Stages (1B1 - 4)
Prospective Multicentric European trial for Cervical cancer, not previously treated, with tumour biopsies, and blood collection for molecular analysis at predetermined time points.
- Trial name
- BIO-RAIDs (NCT02428842)
- Testing
- Tumor biopsies, Blood sampling
- Where
- 24 sites in France, Germany and 3 more
- Volunteers
- 419 people
- Sponsor
- Institut Curie
Thyroid Cancer
To Compare The Effects Of Two Doses Of Vandetanib In Patients With Advanced Medullary Thyroid Cancer
The purpose of this study is to give patients with medullary thyroid cancer either 300mg/day or 150mg/day vandetanib and compare how well each dose affects how their cancer responds.
- Trial name
- NCT01496313
- Testing
- 300mg vandetanib, 150mg vandetanib
- Where
- 30 sites in United States, Czechia and 7 more
- Volunteers
- 81 people
- Sponsor
- Sanofi
Parathyroid Carcinoma, Parathyroid Neoplasm
Parathyroid Cancer Versus Atypical Parathyroid Neoplasm; Investigating Their Clinical Characteristics and Biological Behavior
Objectives: 1. Identify the clinical characteristics of parathyroid (PTH) cancer and PTH atypical neoplasms 2. Investigate if PTH carcinoma and atypical neoplasm present a biological behaviour and have a different impact on the…
- Trial name
- NCT03046524
- Testing
- Chart Review
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- M.D. Anderson Cancer Center
CIN3, CIN2
Cervical Cancer Screening With Human Papillomavirus Testing
HPV testing for primary cervical cancer screening of women over 30 years of age is likely to become the standard of care in the near future in many areas of the world.
- Conditions
- CIN3, CIN2, Cervical Cancer
- Trial name
- ESTAMPA (NCT01881659)
- Testing
- HPV screening
- Where
- 12 sites in Argentina, Bolivia and 7 more
- Volunteers
- 50,000 people
- Sponsor
- International Agency for Research on Cancer
Oral Mucositis, Oral Cancer
Oral Care Protocol for the Management of Chemotherapy and Radiation Therapy-Induced Oral Mucositis
The purpose of this study is to determine the effects of a novel oral care protocol on the severity and pain of oral mucositis in patients receiving radiation and/or chemotherapy for head and neck cancers.
- Trial name
- OMDP (NCT02608879)
- Testing
- Oral Mucosa Deterging and Periodontal Debridement (OMDP), Standard of Care Oral Hygiene Instructions, Dental scaling, ultrasonic
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- NYU Langone Health
Squamous Cell Carcinoma of the Head and Neck; Head and Neck Cancer; Head and Neck Carcinoma; Cancer of the Head and Neck
A Study of Nivolumab in Patients With Head and Neck Cancer.
A prospective real world evidence study of Nivolumab use in France in patient with recurrent or metastatic squamous cell carcinoma of the Head and Neck progressing on or after a platinum based therapy
- Trial name
- ProNiHN (NCT04050761)
- Testing
- Nivolumab
- Where
- France
- Volunteers
- 502 people
- Sponsor
- Bristol-Myers Squibb
Uterine Cervical Neoplasms, Triple Negative Breast Neoplasms
A Phase II Study of GV20-0251 in Combination With Anti-PD-1 Monoclonal Antibodies in Patients With Unresectable, Locally Advanced, or Metastatic Solid Tumors.
This is a Phase 2 study of GV20-0251 in combination with anti-PD-1 monoclonal antibodies (including tislelizumab and toripalimab) for the treatment of participants with unresectable, locally advanced, or metastatic solid tumors…
- Conditions
- Uterine Cervical Neoplasms, Triple Negative Breast Neoplasms, Prostatic Neoplasms, Squamous Cell Carcinoma of Head and Neck
- Trial name
- NCT07623642
- Testing
- GV20-0251, anti-PD-1 monoclonal antibodies
- Where
- 2 sites in China
- Volunteers
- 227 people
- Sponsor
- GV20 Therapeutics
Carcinoma, Squamous Cell of Head and Neck, Squamous Cell Carcinoma of the Head and Neck
Ficlatuzumab and Cetuximab in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)
The epidermal growth factor receptor (EGFR) is both oncogene and prognostic biomarker in head and neck squamous cell carcinoma (HNSCC).
- Conditions
- Carcinoma, Squamous Cell of Head and Neck, Squamous Cell Carcinoma of the Head and Neck, Squamous Cell Carcinoma, Head And Neck
- Trial name
- NCT02277197
- Testing
- Ficlatuzumab, Cetuximab
- Where
- 3 sites in United States
- Volunteers
- 14 people
- Sponsor
- James J Lee
Nasopharyngeal Carcinoma, EBV Infection
A Bidirectional Study in Exploring the Dynamic Changes of Plasma and Urine Metabolites of Nasopharyngeal Carcinoma.
The transformation process of nasopharyngeal carcinoma is complex, so it is particularly important to explore the relationship between various disease states on its clinical pathway.
- Trial name
- NCT05682703
- Testing
- Proteomics technology and liquid biopsy
- Where
- China
- Volunteers
- 2,000 people, healthy volunteers welcome
- Sponsor
- Nanfang Hospital, Southern Medical University
Small Cell Lung Carcinoma, Large Cell Neuroendocrine Carcinoma of the Lung
Phase I Study of [225Ac]Ac-ETN029 in Patients With Advanced DLL3-expressing Solid Tumors
The purpose of this study is to evaluate the safety, tolerability, dosimetry and preliminary efficacy of [225Ac]Ac-ETN029 and the safety and imaging properties of [111In]In-ETN029 in patients aged ≥ 18 years with locally advanced…
- Conditions
- Small Cell Lung Carcinoma, Large Cell Neuroendocrine Carcinoma of the Lung, Neuroendocrine Prostate Cancer, Gastroenteropancreatic Neuroendocrine Carcinoma
- Trial name
- NCT07006727
- Testing
- 225Ac-ETN029, 111In-ETN029
- Where
- 8 sites in United States, Canada and 2 more
- Volunteers
- 116 people
- Sponsor
- Novartis Pharmaceuticals
Thyroid Neoplasms
Institut Paoli Calmettes Thyroid Cancer Database
Database of Institut Paoli-Calmettes patients diagnosed with thyroid cancer
- Trial name
- NCT02869620
- Testing
- Data collection
- Where
- France
- Volunteers
- 3,000 people
- Sponsor
- Institut Paoli-Calmettes
HPV Infection
Integration of HPV Vaccination and HPV-based Cervical Screening Into ARV Clinics: the H2VICTORY Trial
A 3-dose HPV vaccination scheme has shown to be safe and immunogenic in people living with HIV (PLWH), although evidence on 1-dose, which is important to improve coverage, is scarce.
- Trial name
- H2VICTORY (NCT05173324)
- Testing
- HPV vaccine, HPV testing, HAV vaccine
- Volunteers
- 8,000 people
- Sponsor
- International Agency for Research on Cancer
Head and Neck Tumors
Randomized, Open-label Economic and Medical Study on the Lymph Node Management of Squamous Cell Carcinoma of the Oral Cavity and Oropharynx Tumor Stage 1 or 2, Nodes 0 (T1-T2 N0) Operable
Currently, patients with cancer of oral cavity or oropharynx T1-T2N0 classified, are treated surgically with systematic lymph node dissection while in 70%, there is no lymph node metastasis.
- Trial name
- SentiMERORL (NCT02855723)
- Testing
- Surgery: GS strategy, Surgery: Classic strategy
- Where
- France
- Volunteers
- 307 people
- Sponsor
- University Hospital, Montpellier
Advanced Esophageal Squamous Cell Carcinoma, Metastatic Esophageal Squamous Cell Carcinoma
A Study Investigating Alternate Schedules of Tislelizumab Plus Chemotherapy in Japanese Patients With First-line Advanced ESCC
The purpose of this study is to evaluate the pharmacokinetic (PK) profile, safety, and efficacy of tislelizumab administered once every 2 weeks (Q2W) or once every 4 weeks (Q4W) in combination with chemotherapy as first-line…
- Trial name
- NCT07733180
- Testing
- Tislelizumab, Oxaliplatin, Leucovorin
- Where
- 4 sites in Japan
- Volunteers
- 30 people
- Sponsor
- BeOne Medicines
Nasopharyngeal Carcinoma, Intensity-Modulated Radiotherapy
Reducing High Risk Primary Tumor Clinical Target Volumes (CTVp1) in Non-metastatic Nasopharyngeal Carcinoma
To evaluate the long-term local control, survival rate, acute and late radiation related toxicities, quality of life after reducing high risk primary tumor clinical target volumes (CTVp1) in non-metastatic nasopharyngeal…
- Trial name
- CTVp1-NPC (NCT05994170)
- Testing
- Reduction CTVp1, Non-reduction CTVp1
- Where
- China
- Volunteers
- 454 people
- Sponsor
- Zhongshan People's Hospital, Guangdong, China
Esophageal Squamous Cell Carcinoma
Combination of Toripalimab and Neoadjuvant Chemoradiotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma
Radical resection is thought to be the mainstay of esophageal cancer treatment. Neoadjuvant chemoradiotherapy (CRT) followed by surgery has become the standard treatment option for locally advanced esophageal squamous cell cancer…
- Trial name
- NCT04644250
- Testing
- Toripalimab, Paclitaxel liposome/Carboplatin, Intensity-modulated radiotherapy
- Where
- China
- Volunteers
- 32 people
- Sponsor
- Wei Ren
Cervical Cancer, HPV DNA
Postoperative ctHPV-DNA for Recurrence Prediction and Adjuvant Treatment Decision-Making in Cervical Cancer
This prospective observational study will evaluate whether changes in circulating tumor human papillomavirus DNA (ctHPV-DNA) after radical surgery can help predict the risk of recurrence in patients with HPV-associated cervical…
- Trial name
- NCT07782697
- Where
- China
- Volunteers
- 580 people
- Sponsor
- Anhui Provincial Hospital
Oncology, Melanoma
Glycan Mediated Immune Regulation With a Bi-Sialidase Fusion Protein (GLIMMER-01)
This is a Phase 1/2, first-in-human, open-label, dose escalation and dose-expansion study of E-602, administered alone and in combination with cemiplimab.
- Conditions
- Oncology, Melanoma, Ovarian Cancer, NSCLC
- Trial name
- GLIMMER-01 (NCT05259696)
- Testing
- E-602, Cemiplimab
- Where
- 13 sites in United States
- Volunteers
- 69 people
- Sponsor
- Palleon Pharmaceuticals, Inc.
Head and Neck Cancer
Cross-Sectional Study of Oral Health in Patients After Parotid-Sparing Radiation Therapy for Head and Neck Cancer
The investigators are conducting research about oral health and saliva to find out more about the impact of radiation therapy on the oral health of patients.
- Trial name
- NCT01663246
- Testing
- Saliva Sample
- Where
- United States
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- University of Michigan Rogel Cancer Center
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.